BRIEF-Abbvie Says Phase 3 Studies Show Continued Repigmentation With Rinvoq Through Week 76

3

Oct 1 (Reuters) – AbbVie Inc.: * ABBVIE – PHASE 3 STUDIES SHOW CONTINUED REPIGMENTATION WITH RINVOQ THROUGH WEEK 76 * ABBVIE – RINVOQ PLUS NB-UVB SHOWS HIGHER REPIGMENTATION THAN RINVOQ ALONE

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)